Migraine is a painful, episodic disease that sometimes develops into a chronic condition. It is one of the most common neurological diseases in clinical practice. Chronic migraines (CM) are a natural progression of chronic migraines, with a frequency of 15 days per month and similar characteristics to migraine attacks.
This report contains market size and forecasts of Chronic Migraine Treatment in Global, including the following market information:
Global Chronic Migraine Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Chronic Migraine Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Drug Treatment Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Chronic Migraine Treatment include Novartis, Pfizer, AstraZeneca, Allergan, GlaxoSmithKline, Eli Lilly, Merck, Johnson&Johnson and Zosano and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Chronic Migraine Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chronic Migraine Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Chronic Migraine Treatment Market Segment Percentages, by Type, 2021 (%)
Drug Treatment
Substitution Treatment
Global Chronic Migraine Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Chronic Migraine Treatment Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Chronic Migraine Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Chronic Migraine Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Chronic Migraine Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Chronic Migraine Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Pfizer
AstraZeneca
Allergan
GlaxoSmithKline
Eli Lilly
Merck
Johnson&Johnson
Zosano
Alder BioPharmaceuticals